A multicenter prospective observational study appraising the effectiveness of the Supera stent after subintimal recanalization of femoro-popliteal artery occlusion: The SUPERSUB II study
- PMID: 38566517
- DOI: 10.1002/ccd.31028
A multicenter prospective observational study appraising the effectiveness of the Supera stent after subintimal recanalization of femoro-popliteal artery occlusion: The SUPERSUB II study
Abstract
Background: Complex femoropopliteal artery disease represents a challenge. The Supera stent holds the promise of improving the results of endovascular therapy for complex femoropopliteal disease.
Aims: We aimed at appraising the early and long-term effectiveness of the Supera stent after successful subintimal angioplasty (SuperSUB strategy) for complex femoropopliteal lesions.
Methods: We conducted a multicenter, prospective, single-arm observational study including consecutive patients at participating centers in whom Supera was implanted after successful subintimal angioplasty for complex femoropopliteal lesions.
Results: A total of 92 patients were included Femoropopliteal arteries were the most common target, and lesion length was 261 ± 102 mm. Most procedures were technically demanding, with antegrade femoral access in 35 (38%) and retrograde distal access in 55 (60%). Supera stent length was 281 ± 111 mm, with 4, 5, and 6 mm devices being most commonly used: 32 (35%), 35 (38%), and 23 (25%), respectively. Technical success was achieved in 100% of subjects, as was clinical success (per subject), whereas procedural success (per subject) was obtained in 98%. At 24 months, freedom from clinically driven target lesion revascularization was 93%, whereas primary patency was 87%. When compared with a similar historical cohort, Supera stent use appeared to be associated with a reduction in resources.
Conclusion: Use of Supera stent after successful subintimal recanalization of complex lower limb arterial lesions yields favorable procedural results, which are maintained over follow-up, and are associated also with a favorable resource use profile.
Trial registration: ClinicalTrials.gov NCT00933270.
Keywords: Supera stent; endovascular therapy; femoropopliteal disease; peripheral artery disease; stent; subintimal angioplasty.
© 2024 Wiley Periodicals LLC.
References
REFERENCES
-
- Shi R, Babu S. Modern approaches and innovations in the diagnosis and treatment of peripheral vascular diseases. Front Biosci (Schol Ed). 2021;13:173‐180.
-
- Saglietto A, Manfredi R, Elia E, et al. Cardiovascular disease burden: Italian and global perspectives. Minerva Cardiol Angiol. 2021;69:231‐240.
-
- Aru RG, Tyagi SC. Endovascular treatment of femoropopliteal arterial occlusive disease: current techniques and limitations. Semin Vasc Surg. 2022;35:180‐189.
-
- Ferraresi R, Palena LM, Mauri G, Manzi M. Tips and tricks for a correct “endo approach”. J Cardiovasc Surg. 2013;54:685‐711.
-
- Giannopoulos S, Armstrong EJ. Newly approved devices for endovascular treatment of femoropopliteal disease: a review of clinical evidence. Expert Rev Cardiovasc Ther. 2019;17:729‐740.
Publication types
MeSH terms
Associated data
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
